We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
cancer: Archive
3 Attractive Medical Stocks to Buy After Earnings
by Shaun Pruitt
Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.
MCKNegative Net Change EXELNegative Net Change EHCNegative Net Change
biotechnology cancer earnings hospitals investing medical pharmaceuticals
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
by Bryan Hayes
As investors, our job isn't to predict an unknowable future.
NVSNegative Net Change LLYNegative Net Change
artificial-intelligence cancer earnings investing large-cap oncology-screening pharmaceuticals semiconductor tech-stocks
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
NEOPositive Net Change NTRAPositive Net Change GHPositive Net Change
cancer genetic-testing genomics oncology-screening smart-health
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
ILMNNegative Net Change
biotechnology cancer genetic-testing genomics oncology-screening smart-health
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
AZNPositive Net Change PFEPositive Net Change MRNANegative Net Change
biotechnology cancer cell-therapy coronavirus earnings gene-therapy immuno-therapy investing medical messenger-rna pharmaceuticals vaccines
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Medical diagnostics leader in prostate cancer is driving 34% sales and 32% EPS growth
LNTHNegative Net Change
cancer medical oncology-screening smart-health
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
GSKPositive Net Change NVSNegative Net Change PFEPositive Net Change MRKNegative Net Change AMGNPositive Net Change GILDNegative Net Change VRTXPositive Net Change IBBPositive Net Change XBIPositive Net Change SBIOPositive Net Change BTECPositive Net Change IBBQPositive Net Change
cancer cell-therapy etfs gene-editing
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
NVONegative Net Change HUMNegative Net Change CHGCYPositive Net Change CSLLYPositive Net Change
biotechnology cancer cell-therapy dividend-investing dividends gene-therapy hmo hospitals immuno-therapy insurance large-cap medical pharmaceuticals vaccines
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
by Shaun Pruitt
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
PFEPositive Net Change
cancer investing medical oncology-screening pharmaceuticals
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Stunning "beat-and-raise" quarter has analysts scrambling to raise estimates and price targets above $110
LNTHNegative Net Change
cancer medical oncology-screening
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
ADAPNo Net Change KMDAPositive Net Change ZYMEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus immuno-therapy inflation medical
Buy this Medical Sector Pioneer Stock
by Shaun Pruitt
Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
GILDNegative Net Change AMGNPositive Net Change MRNANegative Net Change
cancer dividend-investing dividends immuno-therapy medical oncology-screening
How Markets Have Fared Under a Divided Congress
by Bryan Hayes
Markets typically applaud the 'certainty' that comes with a split Congress.
LLYNegative Net Change
cancer dividend-investing dividends earnings immuno-therapy inflation investing large-cap medical oncology-screening pharmaceuticals
Pfizer Earnings Preview: Growth & Diversification is Key
by Shaun Pruitt
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
PFEPositive Net Change JNJNegative Net Change ABBVPositive Net Change
cancer coronavirus dividend-investing dividends earnings hospitals medical oncology-screening pharmaceuticals vaccines
Should Investors Buy Bristol Myers Squibb Stock?
by Shaun Pruitt
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
BMYPositive Net Change PFEPositive Net Change
cancer dividends investing medical oncology-screening
Bull of the Day: Unum Group (UNM)
by Bryan Hayes
Unum Group has consistently enhanced shareholders' value through dividend hikes and share buybacks.
UNMNegative Net Change
cancer dividend-investing dividends earnings finance insurance investing
Bull of the Day: Illumina (ILMN)
by Kevin Cook
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
ILMNNegative Net Change NTRAPositive Net Change
biotechnology cancer dna-sequencing genetic-testing genomics oncology-screening smart-health
Healthcare Outperformance May Signal Short-Term Market Bottom
by Bryan Hayes
This sector outperformance may be a sign the market is nearing a point of selling exhaustion.
JNJNegative Net Change XLVPositive Net Change
biotechnology biotechs cancer coronavirus dividend-investing dividends earnings etfs investing large-cap pharmaceuticals
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
REGNPositive Net Change BMYPositive Net Change
biotechnology cancer cell-therapy coronavirus earnings genetics hospitals immuno-therapy investing large-cap medical medical-devices pharmaceuticals
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
PFEPositive Net Change ABBVPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings investing large-cap medical pharmaceuticals smart-health
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNPositive Net Change GILDNegative Net Change CDMOPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
The Death Rate Soared Last Year - But Not Why You Might Think
by Bryan Hayes
3 Funeral Services Stocks Hitting All-Time Highs
CSVPositive Net Change SCINegative Net Change HIPositive Net Change
cancer consumer-staples coronavirus earnings industrial-products investing medical
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
MLABPositive Net Change DHRPositive Net Change PACBPositive Net Change NTRAPositive Net Change
cancer genetic-testing genomics medical smart-health
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NEOPositive Net Change EXASPositive Net Change NTRAPositive Net Change GHPositive Net Change
biotechs cancer genetics genomics medical